Spine Wave entered full market release of Tempest® Allograft Bone Matrix, marking its entry into the spinal biologics market. The company plans to launch additional products over the next 18 months, including more in the spinal biologics space.
Tempest comprises cancellous and partially demineralized cortical bone. Proprietary processing yields a bone allograft that is osteoconductive and osteoinductive to support bone growth and cellular migration, and the matrix is formulated with bone strands yielding a moldable allograft with handling characteristics to fill a variety of bone voids. Tempest can also be used with Spine Wave’s GraftMag® Graft Delivery System to rapidly deliver large amounts of bone graft into the surgical field. The product can be stored at room temperature with no need for refrigeration or intraoperative reconstitution.
Tempest Allograft Bone Matrix is processed by Aziyo Biologics and distributed by Spine Wave.
“We are very excited to enter the spinal biologics market with Tempest® Allograft Bone Matrix. The product is very well received by surgeons and our sales team and demand has exceeded our expectations so far,” said Laine Mashburn, Spine Wave’s Executive Vice President for Global Marketing and Business Development. “Spine Wave is making great strides towards offering a comprehensive and meaningfully differentiated portfolio of spine products and Tempest Allograft Bone Matrix is just the first of several new Spine Wave products planned for availability over the next eighteen months, including more in the spinal biologics space.”